Display options
Cite
Kim HS, Piao S, Moon KC, et al. Adjuvant Chemotherapy Correlates with Improved Survival after Radical Cystectomy in Patients with pT3b (Macroscopic Perivesical Tissue Invasion) Bladder Cancer. J Cancer. 2015;6(8):750-8doi: 10.7150/jca.12259.
Kim, H. S., Piao, S., Moon, K. C., Jeong, C. W., Kwak, C., Kim, H. H., & Ku, J. H. (2015). Adjuvant Chemotherapy Correlates with Improved Survival after Radical Cystectomy in Patients with pT3b (Macroscopic Perivesical Tissue Invasion) Bladder Cancer. Journal of Cancer, 6(8), 750-8. https://doi.org/10.7150/jca.12259
Kim, Hyung Suk, et al. "Adjuvant Chemotherapy Correlates with Improved Survival after Radical Cystectomy in Patients with pT3b (Macroscopic Perivesical Tissue Invasion) Bladder Cancer." Journal of Cancer vol. 6,8 (2015): 750-8. doi: https://doi.org/10.7150/jca.12259
Kim HS, Piao S, Moon KC, Jeong CW, Kwak C, Kim HH, Ku JH. Adjuvant Chemotherapy Correlates with Improved Survival after Radical Cystectomy in Patients with pT3b (Macroscopic Perivesical Tissue Invasion) Bladder Cancer. J Cancer. 2015 Jun 29;6(8):750-8. doi: 10.7150/jca.12259. eCollection 2015. PMID: 26185537; PMCID: PMC4504111.
Copy Download .nbib Format: NLM
Share it on

J Cancer. 2015 Jun 29;6(8):750-8. doi: 10.7150/jca.12259. eCollection 2015.

Adjuvant Chemotherapy Correlates with Improved Survival after Radical Cystectomy in Patients with pT3b (Macroscopic Perivesical Tissue Invasion) Bladder Cancer.

Journal of Cancer

Hyung Suk Kim, Songzhe Piao, Kyung Chul Moon, Chang Wook Jeong, Cheol Kwak, Hyeon Hoe Kim, Ja Hyeon Ku

Affiliations

  1. 1. Department of Urology, Seoul National University College of Medicine, Seoul, Korea.
  2. 1. Department of Urology, Seoul National University College of Medicine, Seoul, Korea ; 3. Department of urology, Yanbian University Hospital, Yanji, Jilin Province, China.
  3. 2. Department of Pathology, Seoul National University College of Medicine, Seoul, Korea.

PMID: 26185537 PMCID: PMC4504111 DOI: 10.7150/jca.12259

Abstract

OBJECT: To elucidate the impact of adjuvant chemotherapy (ACH) on survival in patients with urothelial carcinoma of the bladder (UCB) diagnosed with pT3 disease (perivesical tissue invasion).

METHODS: We reviewed the clinical data of 424 patients who underwent radical cystectomy (RC) with bilateral pelvic lymphadenectomy for UCB in our institution between 1991 and 2012. None of the patients received neoadjuvant chemotherapy. Of all patients, 101 (23.8%) were diagnosed with pT3 disease: pT3a in 43 patients and pT3b in 58 patients. The Kaplan-Meier method with the log-rank test was used to estimate and compare overall survival (OS) and cancer-specific survival (CSS) between groups. Multivariate Cox proportional hazard models were used to identify predictors of OS and CSS.

RESULTS: Five-year OS (48.5% vs. 45.6%) and CSS (56.1% vs. 56.2%) were similar in the pT3a and pT3b groups (p = 0.658 and 0.840, respectively). In all pT3 patients, ACH administration was an independent predictor for OS (p = 0.018), but not CSS (p = 0.623) on multivariate analyses. On multivariate analysis according to the pT3 sub-stage, ACH was significantly associated with improved OS (hazard ratio [HR] 0.35; 95% confidence interval [CI] 0.17-0.72, p = 0.004) and CSS (HR 0.33; 95% CI 0.10-0.85, p = 0.022) in only the pT3b group.

CONCLUSION: Our data suggest that in pT3b disease, characterized by macroscopic perivesical tissue invasion, patients may obtain an OS benefit from the administration of ACH. Thus, our findings provide evidence for establishing appropriate indications for ACH in muscle invasive UCB.

Keywords: adjuvant chemotherapy; perivesical tissue invasion; radical cystectomy; survival; urothelial carcinoma

References

  1. Cancer. 2009 Feb 15;115(4):770-5 - PubMed
  2. Urology. 2005 Apr;65(4):697-702 - PubMed
  3. Ann Oncol. 2014 Oct;25(10):1930-4 - PubMed
  4. Eur Urol. 2013 Feb;63(2):234-41 - PubMed
  5. Urology. 2007 Aug;70(2):257-62 - PubMed
  6. Eur Urol. 2014 Apr;65(4):778-92 - PubMed
  7. Int Urol Nephrol. 2013 Apr;45(2):387-93 - PubMed
  8. Eur Urol. 2014 Jul;66(1):42-54 - PubMed
  9. Cancer J. 2009 Sep-Oct;15(5):401-5 - PubMed
  10. BJU Int. 2012 Dec;110(11):1736-41 - PubMed
  11. J Urol. 1999 May;161(5):1494-7 - PubMed
  12. Eur Urol. 2009 Apr;55(4):826-35 - PubMed
  13. World J Urol. 2014 Dec;32(6):1463-8 - PubMed
  14. World J Urol. 2015 Mar;33(3):359-65 - PubMed
  15. N Engl J Med. 2003 Aug 28;349(9):859-66 - PubMed
  16. J Clin Oncol. 2001 Feb 1;19(3):666-75 - PubMed
  17. Cancer. 2014 Jun 1;120(11):1630-8 - PubMed
  18. Eur Urol. 2013 Jan;63(1):58-66 - PubMed
  19. Urology. 2010 Oct;76(4):908-13; discussion 914 - PubMed
  20. J Clin Oncol. 2004 Jul 15;22(14):2781-9 - PubMed
  21. Eur Urol. 2012 Sep;62(3):523-33 - PubMed
  22. J Urol. 2010 Aug;184(2):470-4 - PubMed
  23. Cancer. 1993 Jun 15;71(12):3993-4001 - PubMed
  24. BJU Int. 2010 Aug;106(4):493-9 - PubMed
  25. Ann Oncol. 2012 Mar;23(3):695-700 - PubMed

Publication Types